Answers are grounded in this paper and cite their sources.
is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.
No takes yet. Share an insight, caveat, or question.
Byng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: